News
Astellas and Pfizer have reported five-year follow-up outcomes from the open-label extension of the randomised Phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback